21 results about "Tumor regression" patented technology

Provided is use of a KIF18A inhibitor in preparing a medicament for treating ovarian cancer disease. Pharmacological studies have demonstrated that compounds 1-3 can inhibit the growth of ovarian cancer heterogeneous tumors, and a high dose of the compounds can cause tumor regression in mice. Compared with AMG650, a lower drug exposure of compounds 1-3 reduces the potential drug accumulation toxicity and possesses a significant therapeutic effect on ovarian cancer with good safety.

Provided are an anti-DLL3 antibody or an antigen-binding fragment thereof, a chimeric antigen receptor and a mutant thereof, and an enhanced chimeric antigen receptor comprising a PDL1 antagonist and an mIL7 element. Further provided are a nucleic acid encoding same, an expression cassette, vector and cell comprising the nucleic acid, a preparation method, and a use for preventing, treating, detecting, or diagnosing diseases related to DLL3. In the enhanced DLL3 chimeric antigen receptor, the PDL1 antagonist and the cell membrane IL7 cytokine element play a critical role in a long-term anti-tumor process. Animal efficacy experiments have shown complete tumor regression in all mice, indicating broad application prospects in the pharmaceutical field.

The present invention relates to artificial antigen presenting cell (aAPC) scaffolds to provide cells with specific functional stimulation to obtain phenotypic and functional properties ideal to mediate tumor regression or viral clearance. In particular, the scaffolds of the present invention comprise stabilized MHC class I molecules free of antigenic peptide. The scaffolds can be loaded with antigenic peptide on demand, providing an agile platform for effective expansion and functional stimulation of specific T cells in a peptide-MHC-directed fashion.

Targeting immune checkpoints, such as Programmed cell Death 1 (PD1), has improved survival in cancer patients by unleashing exhausted CD8+ T-cell thereby restoring anti-tumor immune responses. Most patients, however, relapse or are refractory to immune checkpoint blocking therapies. Here, the inventors show that NRP1 is recruited in the cytolytic synapse of PD1+CD8+ T-cells, interacts and enhances PD-1 activity. In mice, CD8+ T-cell specific deletion of Nrp1 improves spontaneous and anti PD1 antibody anti-tumor immune responses. Likewise, in human metastatic melanoma, the expression of NRP1 in tumor infiltrating CD8+ T-cells predicts poor outcome of patients treated with anti-PD1 (e.g. pembrolizumab). Finally, the combination of anti-NRP1 and anti-PD1 antibodies is synergistic in human, specifically in CD8+ T-cells anti-tumor response. Thus the therapeutic inhibition of NRP1 alone or combined with an immune checkpoint inhibitor (e.g. anti-PD1 antibody) could efficiently repress tumor growth in human cancer. The present invention also relates to multispecific antibodies comprising at least one binding site that specifically binds to an immune checkpoint molecule (e.g. PD-1), and at least one binding site that specifically binds to NRP-1. The present invention also relates to a population of cells engineered to express a chimeric antigen receptor (CAR) and wherein the expression of NRP-1 in said cells is repressed.

The present invention relates to a non-invasive magneto-acoustic apparatus for healthy tissue healing and cancer regression comprising at least one pulsed ultrasound unit (LIPUS), at least one permanent magnet, at least one module housing, at least one permanent magnets, at least one control system for controlling pulsed ultrasound unit to energize the unit with desired pulse duration, intensity and active / ON time. The invention is to synchronously use the low intensity pulsed ultrasound (LIPUS) and static magnetic field (SMF) to selectively activate cellular activities specific to cartilage, bone, skin leading to accelerated tissue healing, regeneration. The invention apparatus is to inhibit cancer cellular activities specific to cancers of breast, skin, bone leading to enhanced cancer regression, while leaving the healthy cells unaffected using magneto-acoustic apparatus appropriately. The apparatus exhibit no toxicity to healthy cells and can reduce overall treatment time and costs due to accelerated tissue repair and tumor regression.

The present invention pertains to the use of small molecules in the treatment of cancer. These compounds, which are small-molecule Furin inhibitors, show an ability to enhance sensitivity to immunotherapy and radiotherapy treatments, leading to tumor regression in mice and improved overall survival. Treatment of cancer cells with these compounds resulted in the elimination of the capacity for tumor cells and organoids to grow and invade. These results demonstrate the interest of using these small-molecule Furin inhibitors as therapeutic interventions for cancer patients.

The invention discloses application of 19-hydroxybufalin in preparation of a medicine for treating prostatic cancer, and belongs to the technical field of pharmaceutical preparations. The 19-hydroxybufalin is found to be targeted in vivo and in vitro for the first time, and the growth of prostate tumors is remarkably inhibited, so that the survival basis of tumor cells is fundamentally weakened, programmed death of the tumor cells is triggered, and tumor regression is effectively induced; a brand-new treatment approach is provided, namely, a non-classical drug target, namely HELLS, is degraded in a targeted manner, so that a new treatment choice is expected to be provided for a patient lacking existing target mutation; the provided 19-hydroxybufalin can be used for treating advanced prostate cancer, especially castration-resistant prostate cancer, and a new candidate treatment drug with great potential and a brand new treatment strategy are provided for effectively solving the problem that chemotherapy drug resistance and targeted therapy selection are limited in the castration-resistant prostate cancer at present.

The present invention relates to a FLT3L–flagellin hybrid adjuvant with enhanced antigen cross-presentation efficacy and a vaccine composition comprising same. The hybrid adjuvant of the present invention demonstrated significant therapeutic efficacy as an adjuvant for a therapeutic cancer vaccine in a preclinical mouse model of cervical cancer, resulting in complete tumor regression and sustained protection. In addition, the hybrid adjuvant of the present invention induced tumor-specific antigen CD8+ T cell responses and progenitor-exhausted CD8+ T cells (Tpex) due to an increase in cross-presentation by conventional type 1 dendritic cells (cDC1) in tumor-draining lymph nodes and the tumor microenvironment, and the combination of TCV having the hybrid adjuvant applied thereto and anti-PD-1 therapy significantly improves survival outcomes in anti-PD-1–resistant tumors, and thus can be advantageously applied in anticancer immunotherapy using therapeutic cancer vaccines.

This invention relates to an antitumor agent based on respiratory tract symbiotic bacteria, its preparation method, and its application. Addressing the current clinical issue of the unclear role of respiratory flora in lung cancer patients' progression, we provide the first evidence that the respiratory tract symbiotic *Streptococcus osticulata* possesses antitumor activity. When *Streptococcus osticulata* is delivered back into the respiratory tract, it can stimulate an antitumor immune response, and its efficacy can be further enhanced by adenosylcobalamin. Currently, there is a lack of non-invasive, non-invasive inhaled treatments for lung cancer. The antitumor agent of this invention can be combined with novel non-invasive inhaled bacterial-metabolite immunotherapy to achieve a long-term chronic disease management model, representing a safe and transferable treatment approach. In addition to achieving effective lung tumor control when used alone, this therapy can synergistically enhance the efficacy of immunotherapy, inducing complete tumor regression in 50% of tumor-bearing mice.

The invention discloses a head and neck cancer chemotherapy recurrence animal model and a construction method and application thereof, and relates to the technical field of animal model construction. Comprising the following steps: S1, culturing head and neck cancer tumor cells with fluorescence labels under an in-vitro condition; s2, subcutaneously planting the head and neck cancer tumor fluorescent cells in a groin part of a model animal; s3, 5 days after planting, imaging and observing subcutaneous tumor formation of the model animal, and performing periodic chemotherapy; s4, monitoring through a living body imaging system until a tumor fluorescence signal basically disappears, and determining tumor regression; s5, stopping chemotherapy, continuing feeding for 5-6 weeks, and observing the tumor recurrence condition of the model animal to obtain the head and neck cancer chemotherapy recurrence animal model. The method is easy and convenient to operate, short in experimental period and low in consumption, non-invasive dynamic monitoring can be achieved through the living body imaging technology, the variability of the result is small, the success rate is high, and an ideal platform is provided for head and neck cancer recurrence research and drug screening.

The application relates to the fields of biological medicine and gene therapy, and discloses an IL1RN mRNA lipid nanoparticle drug and application thereof. The drug comprises a lipid nanoparticle and IL1RN mRNA encapsulated in the lipid nanoparticle; the IL1RN mRNA encodes a human IL1RN protein; and the lipid nanoparticle comprises ionizable lipids, phospholipids, cholesterol and pegylated lipids. The application encapsulates IL1RN-201 / 203 mRNA in conventional LNP for the first time, completes preparation characterization and in-vivo expression verification, and proves significant antitumor effect in a high-pressure tail vein transposon-induced in-situ KRAS mutant iCCA mouse model, and partial animals achieve complete tumor regression, thereby filling the blank in the field of IL-1 related inflammatory disease gene therapy and having outstanding originality and broad clinical conversion prospect.

The invention relates to the field of medical image processing and artificial intelligence, in particular to a radiosensitivity prediction transfer learning system, which comprises a data preprocessing module for extracting and normalizing genome and PET image features of a patient; the topology maintaining feature decoupling network module constructs a feature space topological structure, and feature decoupling is achieved through manifold homeomorphic mapping; the multi-source-domain adaptive migration module guides adversarial learning based on geodesic distance, and constructs homotopy equivariant mapping to realize cross-domain feature migration; the prediction evaluation module is used for respectively constructing a parotid gland radioactive damage probability prediction network and a tumor recession rate prediction network; the clinical application interface module outputs a prediction result and provides radiotherapy scheme optimization suggestions, the problem of data heterogeneity between different platforms is effectively solved through a topology maintenance feature decoupling network, and the stability and accuracy of the model in cross-platform application are improved.

The invention relates to an anti-tumor preparation based on respiratory tract symbiotic bacteria as well as a preparation method and application thereof, and provides evidence for the first time aiming at the problem that the respiratory tract flora of a lung cancer patient is not exact in lung cancer progression clinically at present, and the evidence shows that the respiratory tract symbiotic bacteria oral streptococcus has an anti-tumor effect; when the oral streptococcus is delivered back to the respiratory tract, the anti-tumor immune response can be stimulated, and the curative effect of the oral streptococcus can be further enhanced through cobamamide. At present, a non-invasive and non-invasive inhalation type treatment mode for treating lung cancer is lacked clinically, and the anti-tumor preparation can be combined with a novel non-invasive inhalation type bacterium-metabolite immunotherapy to realize a long-term chronic disease management mode, and is a safe and convertible treatment means. On the basis that effective lung tumor control can be realized through independent use, the therapy can synergistically enhance the curative effect of immunotherapy, and tumors are induced to completely subside on 50% of tumor-bearing mice.

The present invention pertains to the use of small molecules in the treatment of cancer. These compounds, which are small-molecule Furin inhibitors, show an ability to enhance sensitivity to immunotherapy and radiotherapy treatments, leading to tumor regression in mice and improved overall survival. Treatment of cancer cells with these compounds resulted in the elimination of the capacity for tumor cells and organoids to grow and invade. These results demonstrate the interest of using these small-molecule Furin inhibitors as therapeutic interventions for cancer patients.

Disclosed herein are methods of inhibiting tumor growth or producing tumor regression in a subject by administering to the subject a therapeutically effective amount of a combination of palbociclib and RAD1901.

The invention provides an application of CHCHD4 in preparation of a medicine for treating cancers. Specifically, the preparation for promoting CHCHD4 expression can be applied to preparation of drugs for treating cancers. The invention provides a treatment strategy for inhibiting tumor metastasis of triple negative breast cancer cells and promoting tumor regression through transcriptional activation of CHCHD4 genes. According to the treatment strategy, expression of CHCHD4 is activated and enhanced through gene transcription, metabolism and immune microenvironment of tumor cells are regulated and controlled, a new targeting strategy is provided for treatment of triple negative breast cancer, and important clinical application prospects are achieved.

The invention relates to the technical field of biological medicine, and provides application of combination of a BCAT1 inhibitor and an immune checkpoint inhibitor in preparation of a cancer treatment product, and the BCAT1 inhibitor inhibits BCAT1 mono-ubiquitination and / or nuclear translocation; the application of the BCAT1 inhibitor comprises any one of the following applications: 1) application in preparation of cancer treatment drugs; and 2) application in preparation of a sensitizer for tumor immunotherapy, wherein the tumor immunotherapy is immune checkpoint inhibitor treatment. The invention has the advantages that the tumor immune microenvironment is regulated and controlled through the non-enzymatic function of the targeted branched chain amino acid metabolic enzyme BCAT1, so that the cancer immunotherapy curative effect is enhanced, the small-molecule inhibitor of the specific targeted BCAT1 is provided, and the small-molecule inhibitor not only has an anti-tumor effect, but also can generate a remarkable synergistic effect with an anti-PD-1 therapy, effectively drives tumor regression, and has a good application prospect. The curative effect is better than that of single therapy. The inhibitor does not influence the catalytic activity of the BCAT1, so that a new precise treatment strategy is provided for overcoming the drug resistance of immunotherapy.

The present disclosure relates to the field of radiotherapy, in particular, methods of and apparatus for treating cancer using ultra-high dose rate radiotherapy (FLASH). The apparatus may comprise a device configured to administer to the subject no more than five fractions of proton ultra-high dose rate radiotherapy (FLASH), said fractions having a range of radiation from 1.5 Gy to 60 Gy, collectively. The device may be configured such that the treatment is sufficient to prevent further growth of the tumor for at least 10% longer than standard of care radiotherapy, induce at least 10% more tumor regression than standard of care radiotherapy and / or delay tumor regrowth by at least about 2 months longer than standard of care radiotherapy.

PKC inhibitors are disclosed. The PKC inhibitors are useful for treating PKC associated diseases, including certain cancers. The PKC inhibitors have improved efficacy at lower dosage amounts to achieve tumor regression, improved potency, PK profile, absorption, gastrointestinal tolerance and kinase selectivity.

The present application has found that near-infrared light immunotherapy targeting CD25 results in unique, fast, and spatially selective depletion of Tregs, which results in treated tumor regression and induces systemic immune responses in untreated tumors. Based on these observations, compositions and methods are provided for killing immunosuppressive cells, for example, to treat cancer. Reducing the number of suppressor cells in a subject may eliminate suppression of effector T cells, such as using the subject's own immune system to treat cancer. In particular embodiments, the methods include contacting a suppressor cell having a suppressor cell surface protein with an antibody-IR700 molecule wherein the antibody specifically binds to the suppressor cell surface protein, and in some embodiments, the antibody does not have a functional Fc region. The cells are then irradiated, e.g., at a wavelength of 660 to 740 nm, e.g., at a dose of at least 4 J cm-2.